# Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase

> **NCT00630747** · PHASE2,PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 94 (actual)

## Conditions studied

- Hunter Syndrome
- Mucopolysaccharidosis II (MPS II)

## Interventions

- **BIOLOGICAL:** Idursulfase

## Key facts

- **NCT ID:** NCT00630747
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-13
- **Primary completion:** 2008-01-31
- **Final completion:** 2008-01-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630747, "Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00630747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*